Prime Medicine (PRME) Stock Analysis & AI Equity Report
Prime Medicine (PRME) overview
Prime Medicine (PRME) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 4.6m and operating profit of USD -208m; the year-end share price was 3.47 USD and market capitalisation was USD 626m. Prime Medicine is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Prime Medicine's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Prime Medicine
Prime Medicine develops genetic medicines using Prime Editing, a gene-editing technology designed to make targeted changes to genomic DNA. Its pipeline includes in vivo programs for liver diseases and cystic fibrosis, and partnered ex vivo programs, including work with Bristol Myers Squibb. The company also develops delivery and editing platforms to support therapeutic candidates for genetic diseases.
Generate the Prime Medicine report
Prime Medicine is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Prime Medicine and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Prime Medicine
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.